Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG today and set a price target of CHF120.00. The company’s shares opened today at CHF105.22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Papadakis is a 4-star analyst with an average return of 4.1% and a 53.66% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Sanofi, and Novartis AG.
In addition to Deutsche Bank , Novartis AG also received a Buy from TR | OpenAI – 4o’s Veda Pharmyne in a report issued on September 20. However, on September 26, Bank of America Securities maintained a Hold rating on Novartis AG (Six Swiss: NOVN).
NOVN market cap is currently CHF200.3B and has a P/E ratio of 17.60.
Read More on CH:NOVN:
Disclaimer & DisclosureReport an Issue
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer
- Trump Trade: White House announces drug pricing deal with Pfizer
- Trump outlines plan for next round of Medicare drug price talks, Bloomberg says
- Immatics appoints Venkat Ramanan as Chief Financial Officer
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)